Lupus & antiphospholipid syndrome
Risk of diabetes mellitus in systemic lupus erythematosus: systematic review and meta-analysis
Authors' conclusion
Although there was no increased risk of DM in patients with SLE compared with controls, HCQ users or adherents had a decreased risk, whereas glucocorticoid users had an increased risk.
Study context
- Population
- Patients with SLE in cohort and cross-sectional studies (PubMed, Embase, Cochrane Library, Web of Science, inception to February 2023)
- Participants
- 266,537 patients37 studies
- Comparison
- SLE vs controls
- SLEn = 266,537
- Outcome
- Risk of DM
Methodological detailsfixed- or random-effects meta-analysis
- Fixed- or random-effects meta-analysis
Pooled result
As reported in the abstract
SLE vs ControlsEstimate (95% CI)P value
Cross-sectional studies
OR 1.05(0.87–1.27)
P = 0.63Cohort studies
RR 1.32(0.93–1.87)
P = 0.12Further pooled results
DM risk with antimalarials and GC (cohort studies)
- Several cohort studies consistently demonstrated a reduced risk of diabetes with antimalarials
- GC use associated with an increased risk of developing diabetes
Risk factors for DM in SLE
- Age, sex, hypertension and immunosuppressants not identified as risk factors
Original publication
Risk of diabetes mellitus in systemic lupus erythematosus: systematic review and meta-analysis. Rheumatology (Oxford). Published 29 March 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →